Abstract
Background: This study examines the structural adaptability of pharmaceutical supply chains in South Africa amidst the COVID-19 disruptions. It highlights the importance of responsive and flexible supply chain frameworks in managing the unprecedented challenges posed by the pandemic.Purpose of the study: The aim is to explore how pharmaceutical supply chain professionals in South Africa have adapted to the rapid changes and severe disruptions caused by the COVID-19 pandemic, with a focus on identifying resilient practices that can inform future supply chain strategies. Design/Methodology/Approach: Employing a qualitative research design, the study gathered insights from 25 pharmaceutical supply chain experts through semi-structured in-depth interviews. Thematic analysis using ATLAS.ti software was utilised to extract prevalent themes, offering a nuanced understanding of the sector's response to the pandemic. Findings: The findings reveal significant adaptations within supply chains, including rapid shifts in logistics and distribution strategies, the adoption of technological advancements, and increased collaboration among stakeholders. These adaptations reflect a strategic pivot towards enhancing structural flexibility to navigate the volatile market conditions induced by the pandemic.Recommendations/value: The study advocates for the integration of advanced technological solutions, stronger stakeholder partnerships, and enhanced agility within supply chain operations. Emphasising the importance of proactive risk management and adaptive planning to bolster the supply chain's resilience against future disruptions. Managerial Implications: The insights provided underscore the need for supply chain managers to develop a robust, adaptive framework, enabling proactive responses to global supply chain disruptions. The findings emphasise the strategic value of agility, technological integration, and collaborative innovation in strengthening supply chain resilience, offering a blueprint for navigating future challenges in the pharmaceutical sector.